Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …

Introduction Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus.
Standard-of-care immunosuppressive therapies achieve poor complete renal response …

Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore,
complement plays a vital role in the pathogenesis of SLE. In general, complement levels in …

Objectives To determine the effect of antimalarial agents (AMA) and different doses and
pharmaceutical forms of belimumab on preventing renal flares in patients with SLE treated …

В настоящее время получены веские доказательства фундаментальной роли
патологической активации В-клеток в патогенезе иммуновоспалительных …

The prevalence of systemic lupus erythematosus (SLE) is higher in Asians than Caucasians,
with higher frequency of renal and other major organ manifestations that carry a poorer …

Owing to its systemic nature with multiple organs potentially being affected concurrently or
sequentially and at varying degrees of severity, the management of systemic lupus …

Background: The aim of this study was to validate the 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for …

Systemic lupus erythematosus (SLE) is a more common autoimmune rheumatic disease in
the Asia‐Pacific region. The prognosis of SLE remains unsatisfactory in some Asian …